ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone440-703-3210
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$80.96 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Viewray (NASDAQ:VRAY) Frequently Asked Questions
What is Viewray's stock symbol?
Viewray trades on the NASDAQ under the ticker symbol "VRAY."
How were Viewray's earnings last quarter?
Viewray Inc (NASDAQ:VRAY) issued its earnings results on Thursday, August, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.09. The company earned $30.17 million during the quarter, compared to analyst estimates of $25.92 million. Viewray had a negative return on equity of 67.02% and a negative net margin of 128.13%. The business's revenue was up 83.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. View Viewray's Earnings History.
When is Viewray's next earnings date?
What guidance has Viewray issued on next quarter's earnings?
Viewray issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80-95 million, compared to the consensus revenue estimate of $118.52 million.
What price target have analysts set for VRAY?
9 Wall Street analysts have issued 1-year price targets for Viewray's shares. Their forecasts range from $5.00 to $15.00. On average, they anticipate Viewray's stock price to reach $9.5556 in the next twelve months. This suggests a possible upside of 180.2% from the stock's current price. View Analyst Price Targets for Viewray.
What is the consensus analysts' recommendation for Viewray?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.
What are Wall Street analysts saying about Viewray stock?
Here are some recent quotes from research analysts about Viewray stock:
- 1. Northland Securities analysts commented, "We remain confident in our analysis of the clinical benefits of MRgRT, and this study is another data point towards long-term validation." (8/19/2019)
- 2. According to Zacks Investment Research, "ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio. " (8/16/2019)
- 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 PT on VRAY. 1Q revenue of $20.3MM (-23%) was essentially in line with FactSet consensus of $20.4MM. We think the order beat is a better measure of the momentum of the business. VRAY received orders for seven MRIdians, two more than we were expecting for the second straight quarter. We think the order momentum is a direct result of the strategy that the new management team has implemented since taking over in July 2018. The finishing touches of management’s strategy are still coming together, but we think VRAY is positioned to capitalize on what we expect to be meaningful shift to adaptive therapy and MR linacs." (5/2/2019)
Has Viewray been receiving favorable news coverage?
Press coverage about VRAY stock has been trending negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Viewray earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Viewray.
Who are some of Viewray's key competitors?
Some companies that are related to Viewray include Natus Medical (BABY), Natus Medical (NTUS), InMode (INMD), AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), BioLife Solutions (BLFS), Zynex (ZYXI), Semler Scientific (SMLR), Stereotaxis (STXS), Rockwell Medical (RMTI), BioSig Technologies (BSGM), Fonar (FONR), Edap Tms (EDAP) and electroCore (ECOR).
What other stocks do shareholders of Viewray own?
When did Viewray IPO?
(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
Who are Viewray's major shareholders?
Viewray's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Park West Asset Management LLC (7.73%), Perceptive Advisors LLC (5.54%), BlackRock Inc. (4.97%), Vanguard Group Inc. (3.73%), Bamco Inc. NY (1.90%) and Cortina Asset Management LLC (1.49%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray.
Which major investors are selling Viewray stock?
VRAY stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Prudential Financial Inc., Candriam Luxembourg S.C.A., Morgan Stanley, Cortina Asset Management LLC, BNP Paribas Arbitrage SA, Brasada Capital Management LP and Pennsylvania Trust Co. View Insider Buying and Selling for Viewray.
Which major investors are buying Viewray stock?
VRAY stock was purchased by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Perceptive Advisors LLC, D. E. Shaw & Co. Inc., Granite Investment Partners LLC, Asymmetry Capital Management L.P., Marshall Wace North America L.P., Bamco Inc. NY and Nuveen Asset Management LLC. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray.
How do I buy shares of Viewray?
Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Viewray's stock price today?
One share of VRAY stock can currently be purchased for approximately $3.41.
How big of a company is Viewray?
Viewray has a market capitalization of $335.82 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. View Additional Information About Viewray.
What is Viewray's official website?
How can I contact Viewray?
Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]
MarketBeat Community Rating for Viewray (NASDAQ VRAY)
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
